ClinicalTrials.gg
CompletedNCT01362439Updated Jun 5, 2013Results posted

Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years

A Phase 4 interventional study of Paliperidone ER in Schizophrenia, sponsored by Janssen-Cilag S.p.A.. Completed. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2013-06-05.

Sponsored by Janssen-Cilag S.p.A. (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
133
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
65th of 115
133 · median 178
Started
2009
with 10 others
Phase 4
42 of 115
5 open now
Registered
64th of 115
by date

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 65th largest by enrollment, is one of 11 that started in 2009, is one of 42 in phase 4, and was the 64th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness and safety of paliperidone extended release (ER) in symptomatic participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) who were receiving treatment with any oral (having to do with the mouth) antipsychotic medication and who needed to be switched to paliperidone ER from the current oral antipsychotic therapy due to insufficient efficacy or due to side effects.

Read the detailed description

This is an open-label (all people know the identity of the intervention), multi-centric (conducted in more than one center) and non-comparative study of paliperidone ER in participants with schizophrenia who have a previous history of bad adherence to the antipsychotic treatment because of insufficient efficacy and side-effects. All the eligible participants will receive a dose of paliperidone ER in range of 3 to 12 milligram (mg) orally (taken by mouth; to be swallowed) once daily for 13 weeks. Efficacy and safety will primarily be evaluated by Positive and Negative Syndromes Scale (PANSS) and Extrapyramidal Symptom Rating Scale (ESRS), respectively. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Paliperidone
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants meet the Fourth Edition (DSM-IV) criteria for schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self)
  • Positive and Negative Syndrome Scale (PANSS) total score at Baseline of greater than equal to 70 and less than equal to 100
  • Participants who need to be switched from the current oral antipsychotic therapy because of lack of efficacy or side effects
  • Participants followed as outpatients
  • Female participants must be for at least 1 year, surgically sterile or, if sexually active, be practicing an effective method of and female participants of must also have a negative urine pregnancy test at Baseline

Exclusion criteria

Exclusion Criteria:

  • Acute psychotic relapse that requires hospitalization and first antipsychotic treatment ever
  • Participants who had received clozapine during the previous 3 months
  • History or current symptoms of tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body) and neuroleptic malignant syndrome (high fever, rigid muscles, shaking, confusion, sweating more than usual, increased heart rate or blood pressure, or muscle pain or weakness)
  • Pregnant or breast-feeding female
  • Participated in an drug trial in the previous 30 days
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    Paliperidone ER

    Drug: Paliperidone ER

Interventions

  • Participants will be administered paliperidone extended release (ER) tablets orally (taken by mouth; to be swallowed) once daily in the dose range of 3 to 12 milligram (mg) for 13 weeks. Dose will be increased or decreased as per Investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Week 13

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening.

    Time frame: Baseline and Week 13

Secondary outcomes

  1. Change in Positive and Negative Syndrome Scale (PANSS) - Positive Subscale Score at Week 13

    The PANSS Positive Subscale assesses seven positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).

    Time frame: Baseline and Week 13

  2. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Negative Subscale Score at Week 13

    The PANSS Negative Subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).

    Time frame: Baseline and Week 13

  3. Change in Positive and Negative Syndrome Scale (PANSS) General Psychopathology Subscale Score at Week 13

    The PANSS General Psychopathology Subscale Score assesses 16 general psychopathology symptoms. The symptoms are rated on a 7-point scale, with a range of 16 (absent) to 112 (extreme psychopathology).

    Time frame: Baseline and Week 13

  4. Percentage of Participants With Greater Than or Equal to 30 Percent Treatment Response in Total Positive and Negative Syndrome Scale (PANSS) Score

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening.

    Time frame: Baseline and Week 13

  5. Change From Baseline in Subjective Well-being Under Neuroleptic (SWN 20) Scale at Week 13

    The SWN 20 scale is a 20 item scale that was originally designed to explore the subjective experience of psychotic participants. The SWN scale contains five sub-scales consisting of four items each: mental functioning (MF), self control (SC), emotional regulation (ER), and social integration (SI), physical functioning (PF). The total score ranges from a minimum of 20 (poor subjective experience) to a maximum of 120 (excellent subjective experience). SWN scores appear to correlate with measure of objective psychopathology, quality of life and other self-ratings of mood.

    Time frame: Baseline and Week 13

  6. Change From Baseline in Drug Attitude Inventory (DAI 30) Scale at Week 13

    The DAI is a 30-item self-rating inventory that focuses on subjective effects of neuroleptic medications in participants with schizophrenia. There are 15 items that are scored as true and 15 scored as false if the person is fully compliant (positive subjective response). Positive answers score as +1, negative answers score as - 1. Questionnaire allows identifying participants at high risk of low compliance. The total score may vary from -30 to +30 with a high total final score is a positive subjective response (compliant) and a low total score is a negative subjective response (non-compliant).

    Time frame: Baseline and Week 13

  7. Clinical Global Impression-Severity Scale (CGI-S)

    The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to normal, not at all ill and a rating of 7 is equivalent to among the most extremely ill participants. Higher scores indicate worsening.

    Time frame: Baseline and Week 13

  8. Change From Baseline in Personal and Social Performance Scale (PSP) at Week 13

    The PSP is 100-point validated clinician-rated scale that assesses degree of difficulty in 4 areas of functioning: socially useful activities, personal and social relationships, self-care, disturbing and aggressive behaviors rated on 6-point scale (1=absent to 6=very severe).Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning, with higher transformed score indicating better function. Total score is divided into 3 levels: 71-100 (mild difficulty); 31-70 (marked difficulty) and 1-30 (severe difficulty).

    Time frame: Baseline and Week 13

  9. Quality of Sleep Score

    This self-administered scale rates quality of sleep and daytime drowsiness. Participants indicate on an 11-point scale how well they have slept in the previous 7 days, from 0 (very badly) to 10 (very well); and how often they have felt drowsy within the previous 7 days, from 0 (not at all) to 10 (all the time). On the sleep evaluation scale, score 0 corresponds to very badly and score 10 to very well.

    Time frame: Baseline and Week 13

  10. Daytime Drowsiness Evaluation Scale

    This self-administered scale rates quality of sleep and daytime drowsiness. Participants will indicate on an 11-point scale how well they have slept in the previous 7 days, from 0 (very badly) to 10 (very well); and how often they have felt drowsy within the previous 7 days, from 0 (not at all) to 10 (all the time).On the daytime drowsiness scale, score 0 corresponds to not at all and score 10 to all the time.

    Time frame: Baseline and Week 13

  11. Extrapyramidal Symptoms Scale (ESRS) Subscale Scores and Total Scores

    Extra pyramidal symptoms attributed to antipsychotic assessed by ESRS scale. Included 4 subscales; Parkinsonism (Park),dystonia(Dyst),dyskinesia(Dysk),akathisia(Akat),12 items on 4-point scale; (0=absent-3=severe); Park (8 items); Dyst (2 items); Dysk (7 items) all 3 rated on 7-point scale (0=none/normal-6=worst). Additionally, subtotals were calculated; hyperkinesia (item 5, 6 of Park); hypokinesia (item 1-4, 7 of Park); bucco-linguo-masticatory (item 1-3 of Dysk), choreoathetoid movement (item 5, 6 of Dysk). Total score: sum of Park, Dyst \& Dysk subscale, ranged from 0 (normal)-102 (severe).

    Time frame: Baseline and Week 13

07

Results

Posted Jun 5, 2013

Participant flow

Participant flow — Overall Study
MilestonePaliperidone ER
Started133
Completed118
Not completed15
Withdrew: Adverse event1
Withdrew: Lack of efficacy3
Withdrew: Lost to follow-up2
Withdrew: Study medication non-compliant1
Withdrew: Participant who withdrew consent8

Outcome measures

PrimaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Week 13

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening.

Time frame:
Baseline and Week 13
Reported as:
Mean · units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Total Score at Week 13
units on a scalePaliperidone ER
Baseline88.98 ± 10.126
Change at Week 1322.468 ± 17.287
SecondaryChange in Positive and Negative Syndrome Scale (PANSS) - Positive Subscale Score at Week 13

The PANSS Positive Subscale assesses seven positive-symptoms of schizophrenia. Positive symptoms refer to an excess or distortion of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).

Time frame:
Baseline and Week 13
Reported as:
Mean · units on a scale
Change in Positive and Negative Syndrome Scale (PANSS) - Positive Subscale Score at Week 13
units on a scalePaliperidone ER
Baseline21.03 ± 5.2
Change at Week 13-6.55 ± 5.3
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) - Negative Subscale Score at Week 13

The PANSS Negative Subscale assesses seven negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).

Time frame:
Baseline and Week 13
Reported as:
Mean · units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) - Negative Subscale Score at Week 13
units on a scalePaliperidone ER
Baseline23.11 ± 6.4
Change at Week 13-4.82 ± 5.6
SecondaryChange in Positive and Negative Syndrome Scale (PANSS) General Psychopathology Subscale Score at Week 13

The PANSS General Psychopathology Subscale Score assesses 16 general psychopathology symptoms. The symptoms are rated on a 7-point scale, with a range of 16 (absent) to 112 (extreme psychopathology).

Time frame:
Baseline and Week 13
Reported as:
Mean · units on a scale
Change in Positive and Negative Syndrome Scale (PANSS) General Psychopathology Subscale Score at Week 13
units on a scalePaliperidone ER
Baseline44.84 ± 6.5
Change at Week 13-11.31 ± 8.7
SecondaryPercentage of Participants With Greater Than or Equal to 30 Percent Treatment Response in Total Positive and Negative Syndrome Scale (PANSS) Score

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210, higher scores indicate worsening.

Time frame:
Baseline and Week 13
Reported as:
Number · percentage of participants
Percentage of Participants With Greater Than or Equal to 30 Percent Treatment Response in Total Positive and Negative Syndrome Scale (PANSS) Score
percentage of participantsPaliperidone ER
Percentage of Participants With Greater Than or Equal to 30 Percent Treatment Response in Total Positive and Negative Syndrome Scale (PANSS) Score40.5
SecondaryChange From Baseline in Subjective Well-being Under Neuroleptic (SWN 20) Scale at Week 13

The SWN 20 scale is a 20 item scale that was originally designed to explore the subjective experience of psychotic participants. The SWN scale contains five sub-scales consisting of four items each: mental functioning (MF), self control (SC), emotional regulation (ER), and social integration (SI), physical functioning (PF). The total score ranges from a minimum of 20 (poor subjective experience) to a maximum of 120 (excellent subjective experience). SWN scores appear to correlate with measure of objective psychopathology, quality of life and other self-ratings of mood.

Time frame:
Baseline and Week 13
Reported as:
Mean · units on a scale
Change From Baseline in Subjective Well-being Under Neuroleptic (SWN 20) Scale at Week 13
units on a scalePaliperidone ER
Baseline73.81 ± 15.4
Change at Week 136.86 ± 12.8
SecondaryChange From Baseline in Drug Attitude Inventory (DAI 30) Scale at Week 13

The DAI is a 30-item self-rating inventory that focuses on subjective effects of neuroleptic medications in participants with schizophrenia. There are 15 items that are scored as true and 15 scored as false if the person is fully compliant (positive subjective response). Positive answers score as +1, negative answers score as - 1. Questionnaire allows identifying participants at high risk of low compliance. The total score may vary from -30 to +30 with a high total final score is a positive subjective response (compliant) and a low total score is a negative subjective response (non-compliant).

Time frame:
Baseline and Week 13
Reported as:
Mean · units on a scale
Change From Baseline in Drug Attitude Inventory (DAI 30) Scale at Week 13
units on a scalePaliperidone ER
Baseline41.20 ± 5.4
Change at Week 132.0 ± 5.4
SecondaryClinical Global Impression-Severity Scale (CGI-S)

The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to normal, not at all ill and a rating of 7 is equivalent to among the most extremely ill participants. Higher scores indicate worsening.

Time frame:
Baseline and Week 13
Reported as:
Median · units on a scale
Clinical Global Impression-Severity Scale (CGI-S)
units on a scalePaliperidone ER
Baseline4 (2 to 6)
Week 133 (1 to 6)
SecondaryChange From Baseline in Personal and Social Performance Scale (PSP) at Week 13

The PSP is 100-point validated clinician-rated scale that assesses degree of difficulty in 4 areas of functioning: socially useful activities, personal and social relationships, self-care, disturbing and aggressive behaviors rated on 6-point scale (1=absent to 6=very severe).Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning, with higher transformed score indicating better function. Total score is divided into 3 levels: 71-100 (mild difficulty); 31-70 (marked difficulty) and 1-30 (severe difficulty).

Time frame:
Baseline and Week 13
Reported as:
Mean · units on a scale
Change From Baseline in Personal and Social Performance Scale (PSP) at Week 13
units on a scalePaliperidone ER
Baseline56.54 ± 12.47
Change at Week 139.05 ± 10.5
SecondaryQuality of Sleep Score

This self-administered scale rates quality of sleep and daytime drowsiness. Participants indicate on an 11-point scale how well they have slept in the previous 7 days, from 0 (very badly) to 10 (very well); and how often they have felt drowsy within the previous 7 days, from 0 (not at all) to 10 (all the time). On the sleep evaluation scale, score 0 corresponds to very badly and score 10 to very well.

Time frame:
Baseline and Week 13
Reported as:
Mean · units on a scale
Quality of Sleep Score
units on a scalePaliperidone ER
Baseline6.22 ± 2.5
Week 137.08 ± 2.1
SecondaryDaytime Drowsiness Evaluation Scale

This self-administered scale rates quality of sleep and daytime drowsiness. Participants will indicate on an 11-point scale how well they have slept in the previous 7 days, from 0 (very badly) to 10 (very well); and how often they have felt drowsy within the previous 7 days, from 0 (not at all) to 10 (all the time).On the daytime drowsiness scale, score 0 corresponds to not at all and score 10 to all the time.

Time frame:
Baseline and Week 13
Reported as:
Mean · units on a scale
Daytime Drowsiness Evaluation Scale
units on a scalePaliperidone ER
Baseline4.09 ± 2.4
Week 133.30 ± 2.5
SecondaryExtrapyramidal Symptoms Scale (ESRS) Subscale Scores and Total Scores

Extra pyramidal symptoms attributed to antipsychotic assessed by ESRS scale. Included 4 subscales; Parkinsonism (Park),dystonia(Dyst),dyskinesia(Dysk),akathisia(Akat),12 items on 4-point scale; (0=absent-3=severe); Park (8 items); Dyst (2 items); Dysk (7 items) all 3 rated on 7-point scale (0=none/normal-6=worst). Additionally, subtotals were calculated; hyperkinesia (item 5, 6 of Park); hypokinesia (item 1-4, 7 of Park); bucco-linguo-masticatory (item 1-3 of Dysk), choreoathetoid movement (item 5, 6 of Dysk). Total score: sum of Park, Dyst \& Dysk subscale, ranged from 0 (normal)-102 (severe).

Time frame:
Baseline and Week 13
Reported as:
Mean · units on a scale
Extrapyramidal Symptoms Scale (ESRS) Subscale Scores and Total Scores
units on a scalePaliperidone ER
Baseline: ESRS Total Score7.39 ± 13.2
Week 13: ESRS Total Score2.21 ± 4.6
Baseline: Park, Dyst, Dysk and Akat1.86 ± 2.6
Week 13: Park, Dyst, Dysk and Akat0.56 ± 1.1
Baseline: Park4.30 ± 7.3
Week 13: Park1.33 ± 2.8
Baseline: Dyst0.66 ± 3.4
Week 13: Dyst0.15 ± 1.0
Baseline: Dysk Movements0.58 ± 1.7
Week 13: Dysk Movements0.18 ± 0.5
Baseline: Hyperkinesia1.43 ± 3.4
Week 13: Hyperkinesia0.44 ± 1.3
Baseline: Hypokinesia2.66 ± 4.4
Week 13: Hypokinesia0.80 ± 1.6
Baseline: Bucco-Linguo-Masticatory0.21 ± 0.7
Week 13: Bucco-Linguo-Masticatory0.05 ± 0.25
Baseline: Choreoathetoid movements of limbs0.20 ± 0.6
Week 13: Choreoathetoid movements of limbs0.06 ± 0.3

Adverse events

Collected over Baseline up to end of study (Week 13). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paliperidone ER—1/132 (0.8%)21/132 (15.9%)
Most frequent serious events
Most frequent serious events
EventPaliperidone ER
Worsening of SchizophreniaNervous system disorders1/132
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPaliperidone ER
Weight IncreaseMetabolism and nutrition disorders4/132
InsomniaNervous system disorders4/132
Extrapyramidal SymptomsNervous system disorders3/132
HypopiesiaCardiac disorders1/132
Increased Blood PressureCardiac disorders1/132
TachicardiaCardiac disorders1/132
Rash (Mycosis)Skin and subcutaneous tissue disorders1/132
GalactorrhoeaEndocrine disorders1/132
HyperthyroidismEndocrine disorders1/132
AgitationNervous system disorders1/132

Baseline characteristics

Age Continuous
Age Continuous(years)Paliperidone ER
Mean35.3 ± 6.76
Sex: Female, Male
Sex: Female, Male(Participants)Paliperidone ER
Female41
Male91
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2011
First posted
May 30, 2011
Start
Jan 2009
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Jun 5, 2013
Last update
Jun 5, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01362439
Responsible party
Sponsor
First posted
May 30, 2011
Start date
Jan 2009
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Jun 5, 2013
Last update
Jun 5, 2013

Study contacts

Janssen-Cilag S.p.A. Italy Clinical Trial
study director · Janssen-Cilag S.p.A.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion